STRATEC Biomedical AG. Deutsche Bank 39th Annual Health Care Conference

Size: px

Start display at page:

Download "STRATEC Biomedical AG. Deutsche Bank 39th Annual Health Care Conference"

Roy Garrison
5 years ago
Views:

1 STRATEC Biomedical AG Deutsche Bank 39th Annual Health Care Conference Boston, May 8 th, 2014

2 Safe Harbor Statement Forward-looking statements involve risks. This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements. Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

3 Agenda 1. Overview and Business Model 2. The IVD Market 3. Financials 4. Aspects of Future Growth Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

Investment Snapshot Market leader in automation solutions in the diagnostic industry with installed base of more than 10,000 systems across over 20 system families including: - Siemens ADVIA Centaur

4 Investment Snapshot Market leader in automation solutions in the diagnostic industry with installed base of more than 10,000 systems across over 20 system families including: - Siemens ADVIA Centaur - DiaSorin s LIAISON XL - Hologic/Gen-Probe s PANTHER - biomérieux s new VIDAS CAGR revenues since 2010: 8% Guidance revenues 2014 to 2017: 8% - 12% Profitable with revenue of 128 million in 2013 Dividend payments raised over 10 consecutive years LIAISON XL for DiaSorin Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

5 STRATEC in the IVD Value Chain Unique Market Position Diagnostic Companies Blood Banks, Laboratories Patients STRATEC develops and manufactures fully automated analyzer systems and disposables focusing on the high growth segments in diagnostics Partners market systems together with reagents and consumables to laboratories, blood banks and hospitals worldwide Laboratories performing tests and offering service to doctors and patients using reagents from diagnostic companies Growth drivers: Aging population Developing healthcare systems world wide High volume of new tests Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

Business Model STRATEC provides instrumentation, software and automation solutions OEM development and manufacturing More than 2,700 fully automated analyzer systems manufactured in 2013 Wide range

6 Business Model STRATEC provides instrumentation, software and automation solutions OEM development and manufacturing More than 2,700 fully automated analyzer systems manufactured in 2013 Wide range of intellectual property rights Extensive collaboration with partner during design phase STRATEC: Engineering / automation, software, QM Partner: System / reagent / market requirements Systems have long market lifecycles Leads to longstanding partnerships Expanding installed base of systems Product enhancement and extension drives value PANTHER for Hologic Gen-Probe Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

Securing Return on Investment Long-term agreements with partners Milestone payments during development stage Operating sales during series production stage Continuous revenues from consumable sales

7 Securing Return on Investment Long-term agreements with partners Milestone payments during development stage Operating sales during series production stage Continuous revenues from consumable sales Minimum volume commitment Firm purchase orders STRATEC an integral part of partners plans Reliable partnership Shortened development time Integration of analyzer system and reagents Agreed development budget & transfer price High commitment by both partners Simoa HD 1 for Quanerix Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

8 Agenda 1. Overview and Business Model 2. The IVD Market 3. Financials 4. Aspects of Future Growth Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

9 IVD Market Segments IVD Market: ~ 50 billion USD Reagents / Chemistry Instrumentation 80% 5% 15% Instrument Services High Throughput (number of systems) Total instrumentation ~ 7.5 billion USD Low Throughput (number of systems) Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

10 USD billion IVD Instrumentation Market Outsourced vs In House Instrumentation Market % 73% 71% 70% 68% 66% 64% CAGR 3% % 27% 29% 30% 32% 34% 36% CAGR 13% E 2014E 2015E IVD OEM Market IVD In House Market Source: Various sources. Excludes glucose test monitors. Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

11 Global Top 20 - IVD Companies Revenues 2012 (USD billion) 1. Roche Diagnostics SIEMENS Abbott Diagnostics Danaher Thermo Fisher Ortho Clinical Diagnostics Alere Sysmex biomerieux BIO-RAD BECTON DICKINSON Hologic / Gen-Probe CH Werfen QIAGEN DiaSorin Novartis Fujirebio Agilent / Dako Immucor Eiken Chemical 0.3 Source: IVD News / figures adjusted by acquisitions in 2012 / non-public companies estimated / non-reported sector revenues estimated Customer STRATEC Instrumentation Customer STRATEC Data Management Not a STRATEC customer Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

12 Agenda 1. Overview and Business Model 2. The IVD Market 3. Financials 4. Aspects of Future Growth Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

13 Financials at a Glance Key figures as of December 31 ( million) Dec 31, 2013 Dec 31, 2012 Change Sales % EBIT % EBIT margin (%) BPS Consolidated net income % Earnings per share ( ) % Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

14 Sales Full Year Sales as of December 31 million Highest sales in company s history in 2013: 128 million CAGR since 2010: 8% Growth continues: Guidance 2014 to 2017: CAGR 8% - 12% Annual Sales as of 12/31 Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

15 Installed Base & Product Groups As of December 31 Delivered systems & installed base As of December 31 Relative share by product group % % 80% % % 50% 40% % 20% 10% % Number of analyzer systems delivered Installed base (based on a 5 year average life cycle) Analyzer systems Development, service and consulting Replacement parts / disposables Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

16 EBIT & EBIT Margin As of December 31 EBIT in million EBIT margin in % % 21% 20% 19% 18% 17% 16% 15% 14% 13% 12% 11% Improving EBIT margin at 15.2%: - Stabilized share of sales with service parts - Improved gross margin of major systems % EBIT EBIT margin Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

17 cent Earnings per Share EPS as of December EPS at Group tax rate: 19.9% Proposed dividend per share 0.60 (previous year 0.56) EPS as of 12/31 Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

18 Agenda 1. Overview and Business Model 2. The IVD Market 3. Financials 4. Aspects of Future Growth Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

Growth in 2014 and beyond Revenue Growth: Hitting development milestones New product launches and ramp-ups Business Development: Extend innovation leadership Evaluate further niches and external

19 Growth in 2014 and beyond Revenue Growth: Hitting development milestones New product launches and ramp-ups Business Development: Extend innovation leadership Evaluate further niches and external opportunities Extension of development and manufacturing capacities Profitability and Cash flow: Reduction in manufacturing costs Further reduction of working capital requirements Manage development growth Market growth: New tests and technologies Demographic development Outsourcing in the IVD industry Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

Contact STRATEC Biomedical AG Gewerbestr. 37 75217 Birkenfeld Germany Tel: +49 7082 7916-0 Fax: +49 7082 7916-999 www.stratec.com TICKER Symbol: Bloomberg: Reuters: ISIN: SBS.DE SBS:GR SBSG.

20 Contact STRATEC Biomedical AG Gewerbestr Birkenfeld Germany Tel: Fax: TICKER Symbol: Bloomberg: Reuters: ISIN: SBS.DE SBS:GR SBSG.DE DE WKN: Marcus Wolfinger CEO, Chairman of the Board of Management Admitted into Deutsche Börse TecDAX since November 2010 THANK YOU! Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

21 Appendix Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

22 STRATEC Group Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

23 STRATEC Group STRATEC Group Data Management Laboratory Software & Data Management Solutions Instrumentation Developing & Manufacturing Automated Solutions and Services Molecular DNA/RNA Stabilization & Sample Preparation > 500 employees across 3 Business Units in 5 Countries Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

24 Assessment and Evaluation 2013 Operations Group tax rate of 19.9% High focus on working capital Ongoing stabilization of service parts business at 21.3% (2012: 20.4%) Two new major development agreements Slightly improved gross margin for major systems Major development milestones for upcoming launch candidates achieved Market Test volumes remain on low but stable level Smaller system launches in 2013; Further ones to take place in 2014 Ongoing negotiations about further outsourcing projects Focus on regulated instrumentation markets Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

25 Conversion Accounting Methods Change in treatment of development cooperations: Recommendations by German Financial Reporting Enforcement Panel (DPR) Distinction between development cooperations and proprietary development projects Completed during 2013 Balance sheet: Inventory Other intangible assets Contraction of other liabilities through inclusion of milestone payments Clustering: IAS11 and IAS38 P&L: Changes to Amortization Scheme (chronological to quantitative) Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

26 Conversion Accounting Methods Key figures including and excluding amendment items: Consolidated income statement ( 000s) 2013 incl. amendment items 2013 excl. amendment items 2012 incl. amendment items 2012 excl. amendment items Sales 127, , , ,424 EBIT 19,493 20,063 15,578 17,441 Consolidated net income 15,478 15,905 12,449 13,846 Earnings per share ( ) EBIT margin (%) Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

27 Impairment Impairment STRATEC USA Impairment loss of 0.9 million recognized on contact free measurement and capacity calculation technology in STRATEC USA Measure undertaken as a precaution Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

28 Shareholder Structure & Share Shareholder Structure (as of: 12/31/2013) 25.2% 32.7% 42.0% Family of Hermann Leistner & their investment company Treasury stock Institutional investors Retail investors 0.1% Share IPO Aug Capital increase < 10%, Mar < 10%, Sep Number of shares 11,770,245 Share price (05/05/2014) Market capitalization 386 million Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

29 Institutional Shareholders Top 15 as of December 2013 Holder Name Holding Allianz Global Investors Europe, GER 5.2 % Threadneedle Asset Management, UK 4.9 % Montanaro Asset Management, UK 4.8 % Financiere de l Echiquier, FRA 2.9 % BNP Paribas Investment Partners Belgium, FRA 1.9 % ING Investment Management Advisors, NL 1.7 % Skandinaviska Enskilda Banken, DEN 1.4 % AXA Investment Managers, FRA 1.2 % Schroder Investment Management North America, USA 1.2 % Schroder Investment Management, UK 0.9 % Credit Suisse, CH 0.9 % Henderson Global Investors, UK 0.8 % Invesco Asset Management, UK 0.7 % Otus Capital Management, UK 0.7 % Fisher Funds Management, NZ 0.6 % Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th, 2014

30 Analyst Coverage Berenberg Bank Dr. Scott Bardo Phone: Crédit Agricole Cheuvreux Oliver Reinberg Phone : DZ Bank Sven Kürten Phone : Landesbank Baden- Württemberg Volker Stoll Phone : Bryan, Garnier & Co Mathieu Chabert Phone: Commerzbank Daniel Wendorff Phone: Deutsche Bank Gunnar Romer Phone : HSBC Trinkaus & Burkhardt Jan Keppeler Phone : Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

31 Financial Calendar /07-08/ th Annual Healthcare Conference, Deutsche Bank, Boston, USA 05/14/2014 Publication of interim report as of 03/31/ /15/2014 Berenberg Diagnostics Conference, London, UK 06/10-12/2014 UBS Pan European small & midcap conference, London, UK 06/18/2014 Annual General Meeting, Pforzheim, GER 07/23/2014 Publication of interim report as of 06/30/ /03-04/ th Annual Goldman Sachs European Medtech and Healthcare Services Conference, London, UK 09/22-24/2014 German Corporate Conference, Berenberg Bank and Goldman Sachs, Munich, GER 10/22/2014 Publication of interim report as of 09/30/2014 Subject to confirmation and amendments Deutsche Bank 39th Annual Health Care Conference / Boston, May 8 th,

STRATEC Biomedical AG

STRATEC Biomedical AG 11 th Annual European Medtech & Healthcare Services Conference Goldman Sachs London, September 4, 2014 Investment Snapshot Market leader in automation solutions in the diagnostic